Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of JNJ-63723283 (anti-PD-1) in advanced cancers
jRCT2041220131Phase 2Suspended
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of cetrelimab in Neoplasm, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicity (DLT) frequency and severity (Part 1), Overall response rate (ORR) per RECIST v1.1 (Part 2) and 1 more. Started Mar 2023; status: suspended.
02
Drugs
cetrelimab
03
Conditions
Neoplasm
Beyond the preview
Go deeper on jRCT2041220131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220131.